NASDAQ$BPMC
Blueprint Medicines Corp · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
BPMC Q4 2025 — $250.0M revenue
We face substantial competition, which may result in our commercial opportunity being reduced or limited by others commercializing, developing or dis. Blueprint Medicines Corp reported Q4 2025 results. Headline numbers extracted from the Form 10-K press release; narrative is light because this row was processed without an LLM call.
- Revenue: $250.0M.
- Filed on Form 10-K (accession 0001558370-25-000953).
Headline financials
Revenue & EPS history
Blueprint Medicines · Revenue · Quarterly
$250M
Forward guidance
Blueprint Medicines expects continued strong revenue growth in 2025, with AYVAKIT sales driving a projected 45% YoY increase. The company plans to advance its BLU-808 clinical trials and further expand its systemic mastocytosis franchise.
Tailwinds
- Projected revenue growth of 45% YoY in 2025.
- AYVAKIT expected to reach $2B in revenue by 2030.
- Expansion of BLU-808 trials for allergic and inflammatory diseases.
- Further reduction in cash burn expected in 2025.
- Strong cash position to support strategic investments.
Headwinds
- Net loss persists despite improved financial performance.
- High R&D and SG&A expenses remain a challenge.
- Continued reliance on AYVAKIT for revenue growth.
- Uncertainty around BLU-808 regulatory approvals.
- Potential competition in the systemic mastocytosis market.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q4 2025
+2.5%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+6.3%
Avg return
30 days after
68%
27 / 40 earnings
Positive
+24.7%
Q3 2023
Best reaction
-20.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +10.9% | +11.0% | +13.3% | |
| Q4 2025 | -8.1% | -10.9% | -13.4% | |
| Q3 2025 | +4.9% | +10.2% | +14.0% | |
| Q2 2024 | -10.7% | -14.4% | -11.8% | |
| Q1 2024 | +13.0% | +14.3% | +11.2% | |
| Q4 2023 | +17.5% | +18.9% | +17.9% | |
| Q3 2023 | +24.7% | +34.1% | +55.8% | |
| Q2 2023 | -20.7% | -26.6% | -21.2% | |
| Q1 2023 | +8.4% | +4.5% | +12.1% | |
| Q4 2022 | +5.0% | -1.2% | +2.4% | |
| Q3 2022 | -11.1% | -19.0% | -8.5% | |
| Q2 2022 | +18.0% | +34.7% | +46.0% | |
| Q1 2022 | +5.9% | -4.9% | -4.8% | |
| Q4 2021 | -17.0% | -19.9% | -21.9% | |
| Q3 2021 | +7.9% | +6.4% | -3.1% | |
| Q2 2021 | +6.0% | +3.8% | +13.2% | |
| Q1 2021 | -1.0% | — | — | |
| Q4 2020 | +3.8% | — | — | |
| Q3 2020 | -2.2% | — | — | |
| Q2 2020 | -0.8% | — | — | |
| Q1 2020 | +0.7% | — | — | |
| Q4 2019 | +3.5% | — | — | |
| Q3 2019 | +10.4% | — | — | |
| Q2 2019 | -9.2% | — | — | |
| Q1 2019 | +9.0% | — | — | |
| Q4 2018 | +1.4% | — | — | |
| Q3 2018 | -1.4% | — | — | |
| Q1 2018 | +1.3% | — | — | |
| Q4 2017 | +5.5% | — | — | |
| Q3 2017 | +4.8% | — | — | |
| Q2 2017 | -9.8% | — | — | |
| Q1 2017 | -11.6% | — | — | |
| Q4 2016 | +13.0% | — | — | |
| Q3 2016 | +9.9% | — | — | |
| Q2 2016 | +2.4% | — | — | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | +4.6% | — | — | |
| Q3 2015 | +1.4% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +8.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro